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Conversion from cyclosporine A to azathioprine treatment improves
LDL oxidation in kidney transplant recipients. The use of the immuno-
suppressant cyclosporine A (CsA) after transplantation has been associ-
ated with less favorable plasma lipid profiles, which may contribute to the
high incidence of cardiovascular morbidity and mortality in transplant
recipients. Recent studies have suggested that oxidative modification of
LDL plays an important role in the initiation and progression of athero-
sclerosis. It has also been demonstrated that CsA may facilitate lipid
peroxidation in vitro and in vivo. Therefore, we determined several
parameters of LDL oxidizability in renal transplant recipients who were
switched from CsA to azathioprine (AZA)-based immunosuppressive
treatment. The susceptibility of LDL to in vitro oxidation, LDL particle
size, plasma titers of IgG and 1gM antibodies against oxidized LDL and
plasma LDL subclass patterns in 19 renal transplant recipients were
determined during CsA treatment and 16 weeks after these patients were
converted to AZA treatment. In addition, mean arterial pressure was
recorded, and glomerular filtration rate and renal blood flow were
estimated from the clearance of radiolabeled thalamate and hippurate.
After conversion, the plasma concentrations of total cholesterol, LDL
cholesterol and triglyceride decreased, while plasma HDL cholesterol did
not change. During CsA therapy plasma LDL was significantly more
susceptible to in vitro oxidation than during AZA, as reflected by a longer
lag phase during in vitro oxidation (98.9 24.3 vs. 114.7 17.3 mm, P =
0.031). In addition, the LDL size increased (236.5 7.3 vs. 240.7 6.8
nm, P = 0.00001), and the titers of 1gM- and IgG-autoantibodies against
oxidized LDL decreased significantly after patients were converted from
CsA to AZA. The more atherogenic LDL subclass pattern B was present
in 13 out of 19 patients during CsA. In five patients, pattern B changed
into pattern A after conversion. The subclass B pattern was maintained in
eight patients and subclass A pattern in six patients. In all patients the lag
time of in vitro LDL oxidation increased, although the biggest changes
were found in those patients in whom the LDL subclass changed from
pattern B to pattern A. Mean arterial pressure decreased and renal
function improved significantly after conversion. No correlation between
parameters of lipid peroxidation and changes in blood pressure or renal
function upon conversion, underlying renal disease, time since transplan-
tation, or antihypertensive treatment was found. Our study demonstrates
that treatment with CsA increases the susceptibility of LDL to in vitro
oxidation, and also enhances the oxidation of LDL in vivo. In addition,
conversion to AZA results in a more favorable lipid profile, which in
combination with a lower arterial pressure and better renal function may
decrease the risk for atherosclerosis. These factors may account for the
cardiovascular complications during CsA treatment after organ transplan-
tation, and also when CsA is used for other diseases.
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The use of cyclosporine A (CsA) has significantly improved
graft survival after organ transplantation [1]. Unfortunately, pa-
tients treated with CsA often develop hypertension and hyperlip-
idemia [2—6]. These factors may contribute to the development of
cardiovascular disease, which is the most important cause of death
after renal transplantation [7]. It has been found that the use of
CsA is associated with a more atherogenic plasma lipid profile [4,
8, 9]. UsA raises plasma cholesterol concentration, mainly by
increasing the plasma low-density lipoprotein (LDL) cholesterol
fraction, without affecting plasma high-density lipoprotein (HDL)
cholesterol [3, 8]. UsA also influences lipoprotein properties and
appears to increase lipid peroxidation [10]. The susceptibility of
low density lipoproteins to oxidation is also increased by UsA, the
lag phase of in vitro LDL oxidation being inversely correlated with
the amount of UsA in LDL [11]. Moreover, in kidney transplant
recipients on CsA the prevalence of small-dense LDL (corre-
sponding with LDL subclass pattern B), which is more susceptible
for oxidation than large LDL (corresponding with LDL subclass
pattern A), is increased [121. Since Taylor and coworkers demon-
strated that overall lipid peroxidation is increased in kidney
transplant recipients on UsA [13], these factors together may
promote LDL oxidation in vivo. This is also suggested by the
presence of increased autoantibodies against malondialdehyde
LDL in kidney transplant recipients on UsA [12].
Oxidative modification of LDL is thought to play a crucial role
in the onset and progression of atherosclerotic disease [14].
Oxidized LDL contains novel epitopes, which act as chemoattrac-
tants for monocyte and macrophage migration, thus stimulating
the formation of foam cells [151. Oxidized LDL appears to be
toxic for endothelial cells. Galle and coworkers found that after
acute dosing of UsA to rats, the development of UsA-mediated
renal dysfunction was associated with lipid peroxidation [161.
Furthermore, oxidized low density lipoproteins inhibit the activity
of inducible NO-synthase inactivated macrophages in vitro [17,
18]. This reduction in NO production may influence cell-to-cell
interactions and vasomotor tone. In previous studies, conversion
from CsA to azathioprine (AZA)-based immunosuppression led
to the reduction of plasma triglyceride and cholesterol levels [19].
As plasma triglycerides are strongly related to LDL size and LDL
size is related to the susceptibility of LDL to oxidation, LDL
oxidation may also be influenced during conversion from CsA to
AZA.
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To investigate the effects of conversion of UsA to AZA on lipid
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peroxidation, we determined plasma lipid profiles and parameters
of in vitro and in vivo LDL oxidation in renal transplant recipients
before and 16 weeks after discontinuation of CsA and replace-
ment by AZA. In addition, renal hemodynamic parameters and
arterial pressure were measured on both occasions.
Methods
Patients
Patients were recruited among renal transplant recipients who
were enrolled in a prospective randomized clinical trial, which was
designated to evaluate the effects of two different immunosup-
pressive regimens, that is, prednisone combined with CsA or with
AZA, on long-term graft function and incidence of rejection
episodes. For this trial all CsA-treated renal transplant recipients
between 18 and 65 years of age, who were six months or longer
after transplantation, were randomly allocated to either continu-
ation of CsA treatment, or conversion from CsA- to AZA-based
immunosuppression. Patients with diabetes mellitus, proteinuria
over 3 grams per day, previous acute graft rejection, or histolog-
ical evidence of chronic graft rejection were excluded. The first 19
consecutive patients fulfilling these criteria and willing to give
written informed consent were studied.
Study design
The first study was performed while patients were on CsA and
the second study 16 weeks later, when patients were on AZA
therapy. During both studies the patients used the same dose of
prednisone. All antihypertensive medication (beta blockers in 13
patients and calcium channel blockers in 8 patients) was discon-
tinued three days prior to both study sessions. After the first study
AZA was started at a dose of 2 mg/kg daily. Two weeks later the
CsA dose was reduced to 50%, and the prednisone dose was
increased to 30 mg daily. After another two weeks CsA was
withdrawn, and the prednisone was tapered to the baseline dose
within three weeks. If necessary, AZA dose adjustments were
made according to the white blood cell count and hematocrit.
On both study days patients arrived in the cardiovascular
research laboratory after an overnight fast. At arrival they were
weighed and subsequently a small catheter (Venflon; Viggo
Spectramed, Helsingborg, Sweden) was inserted in a forearm vein
of each arm. One catheter was used for the infusion of radiola-
beled thalamate and hippuran for renal function studies, and the
other catheter was used for blood sampling. The study protocol
was approved by the local Medical Ethics Committee.
Measurements
Renal hemodynamics. Effective renal plasma flow (ERPF) and
glomerular filtration rate (GFR) were estimated from the clear-
ance of '311-hippuran and '251-thalamate as desribed earlier [20].
During the renal function studies arterial pressure was measured
by an automated oscillometric device (AccuTorr2; Datascope
Corp., Montvale, NJ, USA). Renal blood flow (RBF) was calcu-
lated by dividing effective renal plasma flow by (1 — hematocrit).
Before the start of the renal function studies a blood sample was
taken for the determination of CsA 12-hour trough blood levels
(CycloTrac SP; IncStar Corp., Stillwater, MN, USA).
Blood sampling. Blood samples were drawn into EDTA-con-
taming polypropylene tubes (final concentration EDTA, I mg/mi)
on ice. Plasma was obtained by low speed centrifugation at 4°C.
To the plasma, sucrose (10 p1 sucrose solution per ml plasma) was
added to a final concentration of 0.6% to prevent LDL aggrega-
tion [21]. Plasma was stored at —80°C until use.
Separation of plasma lipoproteins
Low density lipoproteins were isolated by density gradient
uitracentrifugation as described by Redgrave, Roberts and West
[221. To prevent oxidation of the lipoproteins during ultracentrif-
ugation, 0.1 mM EDTA and 0.005% thiomersal were added to the
gradient solutions. Before use, the solutions were gassed by
nitrogen to remove the oxygen. All runs were for 24 hours at 15°C
and 40,000 rpm in an SW 41 TI Beckman rotor using polyallomere
tubes. HDL cholesterol was determined after precipitation of
apoB containing lipoproteins with heparin/MnCI2 [231. The
plasma LDL cholesterol concentration was calculated using the
Friedewald et a! formula [241.
Low density lipoprotein oxidation
LDL oxidation experiments were carried out using the proce-
dure of Esterbauer [25] monitoring the generation of lipid per-
oxidation products in the presence of 1.66 mrvi CuCl2 at 254 nm,
as described before [121. The lag time was defined as the interval
between initiation of the reaction and the intercept of the tangent
of the slope of the absorbance curve with the time scale axis
expressed in minutes.
LDL size and subclass determination
The LDL subclass patterns were identified by electrophoresis
on 2 to 16% PAGE gels, as described by Austin et al [26]. The gels
were prepared with an LKB 11300 Ultrograd gradient mixer [27].
In each gel, reference sera with known a subclass were applied to
lane one and six of a total 12 lanes. The gels were stained with Oil
Red 0 for lipid and the subclass pattern determination. For the
determination of the LDL size, a set of standard proteins with
known hydrated diameters was run on the same gel as the
samples. The standard proteins (HMW electrophoresis calibra-
tion kit; Pharmacia, Piscataway, NJ, USA) were thyroglobulin
(170 A), ferritin (122 A) and catalase (104 A). The gels were
stained with Coomassie Brilliant Blue R 250. The center of the
most prominent LDL band was marked on the gel. The migration
distance of the bands from the top of the gel was measured. The
average LDL particle diameter was estimated from a quadratic
extrapolation of a plot of the logarithm of the diameter of the
standards versus the migration distance of the standards [281. The
subclass pattern A was assigned to LDL particles with a diame-
ter > 238 nm and the subclass pattern B to LDL particles with a
diameter < 238 nm. The cutoff level was set at 238 nm because
this produced the best separation of the two subclasses on the gels
after electrophoresis [29].
Autoantibodies against malondialdehyde-modified LDL
Plasma titers of lgG and 1gM autoantibodies against MDA-
mod ified LDL were determined by ELISA as described elsewhere
[29]. The antibody titer was defined as the absorbance of the wells
coated with MDA-LDL divided by the absorbance of the wells
coated with native LDL for each plasma sample [30].
Other analytical methods
Plasma cholesterol and triglycerides (Boehringer Mannheim,
Mannheim, Germany) and creatinine (Sigma Diagnostics, St.
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Table 1. Clinical characteristics of 19 renal transplant recipients before
and after conversion from CsA to AZA
CsA AZA P
Male/female 13/6
MAPU mm Hg 116 14 109 12 0.0003
Post-Tx time months 24 5 27 5
Body weight kg 75.7 15.4 76.9 15.2 0.757
Body mass index kg/rn2 24.9 3.5 25.1 3.3 0.696
Prednisone dose mg/day 9.6 2.1 9.6 2.1 0.967
CsA dose mg/kg/day 5.5 1.7 —
CsA 12-hr trough level ng/ml 250 66 —
AZA dose mg/kg/day — 1.8 0.4
GFRh mI/mm 50 14 57 19 0.047
RBF mI/mm 377 97 431 150 0.042
RVRd mm Hg/mI/mm 0.346 0.108 0.283 0.116 0.016
Antihypertensives per patient 1.3 0.3 0.6 0.0001
a Mean arterial pressure
h Glomerular filtration rate/rn2 body surface area
C Renal blood flow
d Renal, vascular resistance
Table 2. Plasma lipid concentrations before and after conversion from
CsA to AZA
CsA AZA P
Total cholesterol mmol/liter 5.9 0.9 5.0 0.7 0.002
LDL cholesterol mmol/liter 3.7 0.7 3.0 0.6 0.001
T-IDL cholesterol mmol/liter 1.1 0.4 1.2 0.4 0.340
Total triglyceride mmol/liter 2.4 1.0 1.7 0.6 0.001
Table 3. Parameters of in vitro and in vivo lipid peroxidation before
and after conversion from CsA to AZA
CsA AZA P
LDL particle size nm 236.5 7.3 240.7 6.8 0.00001
LDL subclass pattern A/B 6/13 11/8 0.191
Lag time mm 98.9 24.3 114.7 17.3 0.031
IgG anti-MDA-LDL titer 1.24 0.15 1.19 0.14 0.028
IgManti-MDA-LDL titer 2.02 0.29 1.78 0.19 0.0001
Louis, MO, USA) were determined using commercially available
test kits.
Statistical analysis. All data are presented as means SD. Data
before and after conversion were compared by a paired Student's
1-test. Correlations between variables were calculated using the
Pearson correlation test. The level of significance was set at P <
0.05.
Results
Patient characteristics
The clinical characteristics of the patients during both treat-
ment periods arc shown in Table 1.
Effect of conversion on plasma lipids and lipoproteins
After conversion total cholesterol, LDL cholesterol and plasma
triglycerides decreased significantly. Plasma HDL cholesterol
concentration was stable (Table 2).
Table 4. Relationship between the plasma concentration of total
cholesterol, LDL and HDL cholesterol and triglycerides, and the
change in LDL subclass pattern following conversion from CsA to AZA
LDL subclass change upon conversion
AtoA BtoA BtoB
Number of patients
Triglyceride m
CsA
6
1.96 0.44
5
1.94 0.55
8
2.96 1.22
AZA 1.74 0.52 1.07 0.13 2.17 0.59
P value 0.140 0.020 0.049
Total cholesterol mM
CsA 5.72 1.02 6.28 0.69 6.00 0.94
AZA 4.93 0.89 4.44 0.67 5.14 0.61
P value 0.212 0.003 0.092
LDL cholesterol m
CsA 3.60 0.70 4.23 0.51 3.50 0.69
AZA 3.15 0.62 2.66 0.64 3.08 0.56
P value 0.274 0.003 0.204
HDL cholesterol m
CsA 1.23 0.33 1.16 0.51 0.98 0.38
AZA 1.38 0.51 1.30 0.53 1.08 0.37
P value 0.529 0.663 0.582
Table 5. Relationship between the lag time of copper chloride-induced
in vitro LDL oxidation and the change in LDL subclass pattern
following conversion from CsA to AZA
LDL subclass
change
Number of
patients
Lag time
CsA
Lag time
AZA P value
A to A 6 122 30 131 19 0.508
B to A 5 84 18 115 10 0.014
B to B 8 90 11 102 10 0.044
Effect of conversion on LDL-particle size and subclass distribution
The mean diameter of LDL particles increased significantly
(236.5 7.3 nm vs. 240.7 6.8 nm, P = 0.00001; Table 3). The
number of patients which had LDL subclass pattern A, represent-
ing the less oxidizable large-size LDL, increased from 6 to 11 out
of 19 patients. None of the patients changed from subclass A to
subclass B, or had a smaller LDL size after conversion. The
changes of plasma lipid concentrations were closely related to the
LDL subclass pattern before conversion. In patients whose sub-
class pattern changed from B to A, the LDL cholesterol, total
cholesterol and triglycerides fell much more than in patients who
had pattern A or B both before and after conversion (Table 4).
Low density lipoprotein oxidation
The mean lag time to copper-induced oxidation increased from
99 24 minutes during CsA, to 115 17 minutes during AZA,
indicating that during AZA, LDL was significantly less susceptible
to in vitro oxidation. The largest increase in lag time upon
conversion occurred in patients whose subclass pattern changed
from B to A. When the LDL subclass pattern did not change, the
lag time remained stable (pattern A to A), or increased slightly
(pattern B to B; Table 5).
Autoantibodies against MDA -modified LDL
The concentration and titer of 1gM autoantibodies against
MDA-LDL fell significantly after conversion (—27% and —16%,
respectively; Table 3). Both before and after conversion patients
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with subclass A had a lower 1gM antibody concentration than
patients with subclass B. The largest decrease in antibody concen-
tration occurred in patients in which the LDL subclass pattern
changed from B to A (54.9 18.5 vs. 32.1 8.4 xg/ml, P
0.0365). The antibody concentration dropped also in the patients
in which the LDL subclass pattern A did not change (34.7 8.5
vs. 23.4 4.5 jxg/ml, P = 0.0170). In patients with a subclass B
pattern before and after conversion, 1gM antibody concentration
was elevated and remained unchanged (48.7 9.1 vs. 41.8 11.6
jxg/ml, P = 0.2075).
Discussion
Cardiovascular disease is the most important cause of death in
renal transplant recipients [7]. This may be related to pretrans-
plant renal replacement therapy, the underlying renal disease that
may be accompanied by elevated blood pressure, or to other
factors. Elevated serum cholesterol and hypertension are well-
known side-effects of CsA, which occur in a significant proportion
of patients. Therefore, the use of CsA may worsen the cardiovas-
cular risk profile of transplant patients.
Recently, it has become clear that the atherogenicity of LDL is,
apart from their plasma concentration, dependent on chemical
modifications such as oxidation [14, 151. Oxidized LDL particles
are avidly taken up by scavenger receptors that are present on
endothelial cells and macrophages and may induce foam cell
formation in vivo [32]. Oxidized LDL may trigger immune reac-
tions in the vessel wall, promote gene expression of cell adhesion
molecules in arterial cells and impair endothelial vasodilator
function [32—34].
Our study demonstrates that conversion from CsA to AZA
leads to a longer lag time of in vitro LDL oxidation, indicating that
LDL particles are less susceptible to oxidative modification during
AZA. In vitro studies have shown that CsA induces lipid peroxi-
dation both in liver and renal microsomes [10]. Recently it has
been demonstrated that the oxidizability of LDL is strongly
correlated to CsA blood concentrations, suggesting that CsA may
facilitate LDL oxidation [11]. Increased lipid peroxidation was
also found in CsA-treated heart transplant recipients [37]. In our
study there was no significant correlation between CsA 12-hour
trough blood concentrations and any of the lipid peroxidation
parameters. The observed effects on LDL oxidation may, apart
from a direct influence of CsA, be caused by the increase in LDL
size following conversion. It has been shown that small LDL
particles, corresponding with pattern B, are more susceptible to
oxidation than large LDL particles, which correspond with pattern
A [36]. A number of our patients shifted from pattern B to A,
while none of them shifted from pattern A to B. Therefore,
besides the loss of the pro-oxidant effect of CsA, the significant
increase in LDL size may have contributed to the decrease in LDL
oxidizability in Vitro.
It is well known that patients with an elevated plasma triglyc-
eride are much more likely to express LDL subclass pattern B, and
have small-dense LDL particles [36, 39]. We also found that
patients with a subclass B pattern had a higher plasma triglyceride
level, and had the largest decrease after conversion. The increased
plasma triglyceride concentrations associated with the use of CsA
may therefore be an alternative explanation for the changes in
lipid peroxidation we have found.
The oxidation of LDL in vivo is reflected by the presence of
autoantibodies against oxidized LDL [381. We found a significant
decrease in plasma concentration of 1gM antibodies against
oxidatively modified LDL following conversion, especially in
patients who had an increase of the lag time to in vitro LDL
oxidation. This suggests that during CsA LDL is more susceptible
to oxidation, which may lead to increased LDL oxidation in vivo.
One may argue that AZA may directly impair antibody produc-
tion. However, in a previous study we have found that during CsA
the production of antibodies against influenza vaccination was
inhibited, rather than during AZA [401.
The increased susceptibility to oxidation during CsA was ac-
companied by a reduction of renal blood flow and glomerular
filtration rate. Recently it has been reported that in uninephrec-
tomized rats treated with different doses of CsA, lipid peroxida-
tion products in renal tissue homogenates and renal vascular
resistance were dose-dependently increased. Both could be pre-
vented by the coadministration of the antioxidant vitamin E,
suggesting that oxidative processes play a causative role in the
pathogenesis of CsA-induced renal injury [41]. However, other
investigators were unable to confirm these findings in humans
[42]. In a cross sectional study, Maggi et al showed that in
hemodialysis patients the titer of autoantibodies directed against
oxidatively-modifled LDL is increased when compared to healthy
controls, suggesting that enhanced LDL oxidation in present in
vivo [43]. In our study no relationship between absolute values or
changes in renal function, in blood pressure or duration of
pretranspiant renal replacement therapy and any of the lipid
peroxidation parameters was present.
Only a few of our study patients developed symptomatic
cardiovascular disease during the post-transplant period. Obvi-
ously, our study population was too small to allow definitive
conclusions about the association between the prevalence of
cardiovascular events and lipid peroxidation in vivo.
In conclusion, this study shows that the susceptibility of LDL to
in vivo and in vitro oxidation appears to be increased during CsA
administration when compared to AZA. In view of recent reports
of the importance of oxidatively modified LDL in the pathogen-
esis of atherosclerosis, our findings offer an additional explanation
for the high cardiovascular morbidity and mortality after renal
transplantation. The molecular mechanism of our observations is
still unresolved. Further studies of the effects of CsA on lipid
peroxidation and its implications for atherogenesis are needed.
Reprint requests to MA. van den Doipel, M.D., Department of Internal
Medicine I, University Hospital Rotterdam, Dr. Molewaterplein 40, 3015 GD
Rotterdam, The Netherlands.
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